Aileen Fraser

Aileen Fraser

Auto-generated profile, based on publicly available information

Aileen Fraser

University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2019 in Gut
Verified
Journal Article
Open access
CLChristopher Andrew Lamb
Christopher Andrew Lamb
NKNicholas Alexander Kennedy
Nicholas Alexander Kennedy
TRTim Raine
Tim Raine
PHPhilip Anthony Hendy
Philip Anthony Hendy
PSPhilip J Smith
Philip J Smith
AHA Barney Hawthorne
A Barney Hawthorne
Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This guideline for management of inflammatory bowel disease in adults over 16 years of age was developed by Stakeholders representing UK physicians (British Society of Gastroenterology), surgeons (Association of Coloproctology of Great Britain and Ireland), specialist nurses (Royal College of Nursing), paediatricians (British Society of Paediatric Gastroenterology, Hepatology and Nutrition), dietitians (British Dietetic Association), radiologists (British Society of Gastrointestinal and Abdominal Radiology), general practitioners (Primary Care Society for Gastroenterology) and patients (Crohn’s and Colitis UK). A systematic review of 88 247 publications and a Delphi consensus process involving 81 multidisciplinary clinicians and patients was undertaken to develop 168 evidence- and expert opinion-based recommendations for pharmacological, non-pharmacological and surgical interventions, as well as optimal service delivery in the management of both ulcerative colitis and Crohn’s disease. Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care. Twenty research priorities to inform future clinical management are presented, alongside objective measurement of priority importance, determined by 2379 electronic survey responses from individuals living with ulcerative colitis and Crohn’s disease, including patients, their families and friends.

26 April 2021 in Gut
Verified
Journal Article
Open access
PDF file
NKNicholas Alexander Kennedy
Nicholas Alexander Kennedy
SLSimeng Lin
Simeng Lin
JGJames R Goodhand
James R Goodhand
NCNeil Chanchlani
Neil Chanchlani
BHBenjamin Hamilton
Benjamin Hamilton
TATariq Ahmad
Tariq Ahmad
Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Design Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared with a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin α4β7 monoclonal antibody. Our primary outcome was anti-SARS-CoV-2 spike (S) antibody concentrations, measured using the Elecsys anti-SARS-CoV-2 spike (S) antibody assay 3–10 weeks after vaccination, in patients without evidence of prior infection. Secondary outcomes were seroconversion rates (defined by a cut-off of 15 U/mL), and antibody responses following past infection or a second dose of the BNT162b2 vaccine. Results Geometric mean (SD) anti-SARS-CoV-2 antibody concentrations were lower in patients treated with infliximab than vedolizumab, following BNT162b2 (6.0 U/mL (5.9) vs 28.8 U/mL (5.4) p<0.0001) and ChAdOx1 nCoV-19 (4.7 U/mL (4.9)) vs 13.8 U/mL (5.9) p<0.0001) vaccines. In our multivariable models, antibody concentrations were lower in infliximab-treated compared with vedolizumab-treated patients who received the BNT162b2 (fold change (FC) 0.29 (95% CI 0.21 to 0.40), p<0.0001) and ChAdOx1 nCoV-19 (FC 0.39 (95% CI 0.30 to 0.51), p<0.0001) vaccines. In both models, age ≥60 years, immunomodulator use, Crohn’s disease and smoking were associated with lower, while non-white ethnicity was associated with higher, anti-SARS-CoV-2 antibody concentrations. Seroconversion rates after a single dose of either vaccine were higher in patients with prior SARS-CoV-2 infection and after two doses of BNT162b2 vaccine. Conclusion Infliximab is associated with attenuated immunogenicity to a single dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab. Trial registration number ISRCTN45176516.

17 April 2020 in Gut
Verified
Journal Article
Open access
PDF file
NKNicholas Alexander Kennedy
Nicholas Alexander Kennedy
GJGareth-Rhys Jones
Gareth-Rhys Jones
CLChristopher A Lamb
Christopher A Lamb
RARichard Appleby
Richard Appleby
IAIan Arnott
Ian Arnott
CLCharlie W Lees
Charlie W Lees
The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government’s advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.

20 August 2025 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
CRChandni Radia
Chandni Radia
YDYaa Danso
Yaa Danso
SRSusan Ritchie
Susan Ritchie
MHMelissa Hale
Melissa Hale
AEAlexander T Elford
Alexander T Elford
KKKlaartje Bel Kok
Klaartje Bel Kok
Background and Aims: Janus kinase inhibitors (JAKi) provide effective treatment for ulcerative colitis (UC), but inadequate response (IR) or intolerance occurs frequently. This study aimed to assess the effectiveness of a second JAKi in a real-world UC cohort. Methods: A retrospective multicenter cohort study encompassing 19 UK hospitals was undertaken. Primary outcome was clinical remission (Simple Clinical Colitis Activity Index/partial Mayo Score ≤ 1) at weeks 8 and 24, based on available assessments. Biochemical (CRP ≤ 5mg/L and fecal calprotectin ≤ 200µg/g) and endoscopic (Ulcerative Colitis Endoscopic Index of Severity/Mayo Endoscopic Subscore ≤ 1) remission were also assessed. Results: A total of 131 patients with active UC were included. The majority (60%) had exposure to ≥3 advanced therapies and 50% required corticosteroids at induction. Clinical remission rates were 59% and 51% at weeks 8 and 24. Biochemical and endoscopic remission rates were 61% and 60% at week 8, and 47% and 32% at week 24. All disease activity parameters significantly reduced by week 8 (P < .001). At week 24 no difference was detected in clinical remission rates between those with primary non-response (42%) or secondary loss of response (52%) to their first JAKi (P = .518). Clinical remission did not differ between upadacitinib (54%) and filgotinib (36%), P = .253. Adverse events occurred in 27% of patients, and serious adverse events in 8%. Conclusions: In this highly refractory cohort with active UC a second JAKi effectively achieved remission following IR to first JAKi. Type of first JAKi failure did not appear to influence clinical remission. No new safety signals were found.

29 September 2010 in Nursing Management
Verified
Journal Article
Closed access
AFAileen Fraser
Aileen Fraser
The author travelled to the United States on a Florence Nightingale Travel Scholarship to study the systems in place to respond to and prevent elder abuse. She visited centres in Orange County, California, and New York City that are involved in dealing with the issue. This article provides a summary of her findings, with emphasis on education and training strategies for healthcare professionals working with older people, and provides recommendations for developments in safeguarding older people in the UK. The author also reviews models of service, models of evaluation and approaches to older people who self-neglect.

8 June 2018 in Gut
Verified
Conference Paper
Open access
PDF file
FCFraser Cummings
Fraser Cummings
CSCatherine Singfield
Catherine Singfield
LJLesley Jones
Lesley Jones
JHJoseph Hickey
Joseph Hickey
Ian BealesIan Beales
Ian Beales
SHSami Hoque
Sami Hoque
Introduction Many patients with inflammatory bowel disease (IBD) experience iron deficiency anaemia (IDA), which can impact significantly on quality of life (QoL). Oral ferric maltol (Feraccru) is a novel iron complex licensed in the UK for the treatment of IDA in patients with IBD. The aim of this study is to understand the early experiences of Feraccru in patients with IBD and IDA in the UK, including treatment effectiveness, patterns of use and tolerability. Methods FRESH is an ongoing observational cohort study conducted in 5 secondary care gastroenterology centres in the UK (up to 8 centres planned). Data were collected from hospital medical records for consenting adult patients (≥18 years) with Crohn’s disease (CD), ulcerative colitis (UC) or unspecified IBD who were also diagnosed with mild or moderate IDA and initiated on Feraccru since June 2016. Patients with an IBD flare at time of study recruitment, and/or requiring corticosteroids to treat flares at time of Feraccru initiation were not eligible for the study. Interim data for the first 30 patients recruited to the study are presented. Results The mean (SD) age of 30 patients at initiation of Feraccru was 42.2 (15.8) years and 37% (n=11) of patients were male. Of these patients, 50% (n=15) had CD, 43% (n=13) had UC and 7% (n=2) had IBD of unspecified type. The mean haemoglobin (Hb) level at initiation was 10.7 g/dL (standard deviation 12.1 g/dL). At 12 weeks after initiation of Feraccru (permitting a measurement window from 10 to 16 weeks), 62% (n=8) of 13 patients with a measurement recorded had normalised Hb levels (defined as Hb ≥12.0 g/dL for females and ≥13.0 g/dL for males). Out of 30 patients who received Feraccru, 10% (n=3) discontinued by week 4 (+1 week) and 23% (n=7) by week 12 (+4 weeks). No patients discontinued Feraccru due to lack of efficacy. Conclusions The first results from a study of the use and outcomes of Feraccru in UK clinical practice show that in the small sample less than half of patients had a recorded Hb measurement at 12 weeks after initiation of Feraccru. Of those who did, 62% had normalised Hb. This is comparable to results from the AEGIS phase III study where 66% patients achieved normalised Hb by 12 weeks.